



What is EURIPID?

EURIPID is a **voluntary and non-profit cooperation** between European countries to maintain and continuously improve a database with information on **national prices and pricing regulations** for medicinal products in a **standardised format**.

What is EURIPID's mission?

EURIPID's mission is to make the pricing of pharmaceuticals more transparent. The members of EURIPID believe, that **improving transparency** is a means to improve patients' **access to affordable medicines**. The **Pharmaceutical Strategy for Europe** also states that the Commission will encourage transparency of price information to help Member States to take better pricing and reimbursement decisions, also considering possible knock-on effects for innovation.

How is EURIPID organised?

1 Board of Participants (BoP)

The BoP takes strategic decisions. The BoP consists of one representative from each participating country or organisation and the members of the Executive Committee, which are not part of the BoP. The chair of the BoP is elected by the participants for three years.


2 Executive Committee

The Executive Committee focuses on the operational level. It consists of one representative of each founder (NEAK and GÖG), three elected members of the Board of Participants (BoP) and a representative of the European Commission (EC).

3 Project team

The project team acts on behalf of the members and is responsible for project management, incl. all activities related to the smooth operation of the project i.e. carrying out the daily work.

Which countries are members of EURIPID?



Current chair of the BoP

Momir Radulović

Executive Director of the Agency for Medicinal Products and Medical Devices of the Republic of Slovenia (JAZMP). His previous work experience includes hospital and community pharmacy and the pharmaceutical industry.



What information does the database contain?

Validate information on pharmaceutical systems from > 28 countries



Information on pharmaceutical prices, volumes and the existence of Managed Entry Agreements



Continuous information on prices (partly dating back to 2010) and volumes (dating back to 2015)



Additional information can be found here: www.euripid.eu

Main areas of activities of EURIPID



Deepening collaboration between European countries and the competent authorities

Providing data to members of the EURIPID collaboration and researchers



Improving transparency in the field of pharmaceutical pricing and reimbursement



Co-funded by the European Union

This information (project deliverable 2.1: Introductory project leaflet) was produced under the project "Development of early warning features and guidance in the area of pricing through the EURIPID database" (Project number: 101100610). EURIPID is co-funded by the European Union as part of the EU4Health Programme (2021-2027). Views and opinions expressed in this leaflet are however those of the grant consortium members only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HaDEA). Neither the European Union nor HaDEA can be held responsible for them.



EURIPID ACCESS Project

Besides its regular activities, EURIPID continuously supports the European Commission in its implementation of the Pharmaceutical Strategy for Europe currently under the following grant:

Name: Call for proposals to develop early warning features and guidance in the area of pricing through the EURIPID database, based on competition cases

Call: EU4H-2022-PJ-08 HS-g22-17.01

Start date: 01.03.2023 **End date:** 31.08.2025

Max. EU contribution: EUR 300,000

The consortium acting on behalf of the EURIPID Collaboration under this grant consists of the following institutions:



National Institute of Health Insurance Fund Management (NEAK), Hungary

Austrian National Public Health Institute (GÖG), Austria



National Institute for Health and Disability Insurance (INAMI-RIZIV), Belgium

National Council on Prices and Reimbursement of Medicinal Products (NCPMP), Bulgaria



Agency for Health Technology Assessment and Tariff System (AOTMiT), Poland

National Authority of Medicines and Health Products (INFARMED, I.P.), Portugal



Agency for Medicinal Products and Medical Devices (JAZMP), Slovenia

Grant-specific milestones of EURIPID

The EURIPID Collaboration is funded by an annual contribution fee of the participants. However, to further develop EURIPID, the Collaboration applies for public funding. From 2023 to 2025, the EURIPID Collaboration has been awarded a grant as part of the EU4Health programme.



Improving the **functionality of the EURIPID database** to better serve the informational needs of national competent authorities on pricing and reimbursement and public healthcare payers (NCAPR) :

- Developing new functionalities
- Monitoring of price developments
- Implementing a notification function

The EURIPID database aims to be the most comprehensive public database on medical technologies. As part of the grant a **feasibility study** will be conducted on how the data content could be extended:

- Geographic scope of data
- Price information on non-reimbursed and hospital only products
- Integration of volume information in an automated way




Capacity building and guidance in the area of pharmaceutical pricing

- Organising webinars and meetings for different target groups
- Demonstrating extended use of the database via use cases
- Proposing an update of the EURIPID Guidance Document on External Reference Pricing (ERP)

Strengthening cooperation with public institutions and stakeholders

- Contributing to NCAPR meetings and discussions in the field by demonstrating the value and usefulness of the database
- Participating and presenting the project and its outputs at conferences / congresses



Project Summary

The institutions of the grant consortium aim to provide guidance in the area of pharmaceutical pricing to national competent authorities on pricing and reimbursement and public healthcare payers (NCAPR). The main tool for this undertaking is the EURIPID database, which provides information on medicines and their prices in a standardised, continuously updated format. The database will be completed with new functionalities to better support its users.

Outlook for the future

In addition to the activities described as part of the grant, EURIPID is keen on supporting and cooperating with international organisations and initiatives including:

- OECD on indicators to measure access to medicines
- WHO on increasing the transparency of pricing / prices
- EUROSTAT's Consumer Good Survey on the prices and price level indices of medicinal products